PD-L1 anticorps (Biotin)

N° du produit ABIN7608339

Cet anticorps anti-PD-L1 est un anticorps Lapin Monoclonal détectant PD-L1 dans FACS et ELISA. Adapté pour Humain.

Aperçu rapide pour PD-L1 anticorps (Biotin) (ABIN7608339)

Antigène: PD-L1 (CD274 (PD-L1))

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-L1 est conjugé à/à la Biotin

Application: Flow Cytometry (FACS), ELISA

Clone: DM123

Détail du produit anti-PD-L1 anticorps (Biotin)

Fonction: Biotinylated Anti-PD-L1 antibody(DM123), Rabbit mAb

Purification: Purified from cell culture supernatant by affinity chromatography

Isotype: IgG

Information d'application

Indications d'application: ELISA 1:5000-10000, Flow Cyt 1:100

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Stock: -20 °C,-80 °C

Stockage commentaire: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Date de péremption: 12 months

Détails sur PD-L1

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: PDL1

Sujet: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints